Nidlegy is partnered with Sun Pharma for the treatment of Skin Cancers in Europe, New Zealand and Australia. Both companies jointly made the following announcements:
– 23 October 2023 – Phase III PIVOTAL trial met the primary endpoint
– 31 May 2024 – Primary results of PIVOTAL presented at ASCO
– 04 June 2024 – MAA submission to EMA
The data of the Phase III Nidlegy trial are expected to be published in a peer-reviewed scientific journal in 2024.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Jul 04 2024 | 3:04 PM IST
The European Tour group has launched a new Awards programme that will honour and showcase the various suppliers that have pioneered sustainable innova
The European Central Bank has intervened to prevent a sharp slowdown in the eurozone economy with its first back-to-back interest rate cut since the euro crisis
InPost Group, described as “Europe’s leading e-commerce logistics enabler”, bought the remaining 70% of Menzies, a newspaper distributor which employ
Mediadrive, Europe’s leading golf advertising agency, is proud to announce its latest partnership with the Ladies European Tour (LET), becoming the